ARTICLES BY RONALD A. RADER

• Cell & Gene Therapy Bioprocessing: Demand For Better Process Control, Expertise & CMOs

  5/14/2021

  Manufacturing capacity for both cell therapies and gene therapy viral vectors remains in short supply. From BioPlan Associates, Inc.'s new survey of biopharmaceutical manufacturing professionals, there is a current and worsening capacity crunch. The industry continues to demand innovative solutions from its suppliers in key areas that can be slow to develop. 

• New Microbiological Methods In Bioprocessing

  4/11/2018

  Testing for evidence of microbial contamination in bioprocessing has a long history — and can be expensive, slow, and burdensome. So suppliers, testing facilities, and regulators have been seeking improvements.

• Overcoming The Manufacturing Hurdles Of Cell & Gene Therapy

  2/20/2017

  A number of innovative cellular and gene therapies are in development, and R&D and investments in these fields are rapidly growing. Although the number of approvals and markets remain very small — negligible by the standards of the mainstream (bio)pharmaceutical industry — this is likely to change as the first clinical trials are successfully concluded.